Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

NY-ESO-1 Encodes DRB1*0401-restricted Epitopes Recognized by Melanoma-reactive CD4+ T Cells

NY-ESO-1 Encodes DRB1*0401-restricted Epitopes Recognized by Melanoma-reactive CD4+ T Cells The NY-ESO-1 gene is expressed by a range of human tumors and encodes HLA-A2-restricted melanoma peptides recognized by CD8+ CTLs. Here we report that the NY-ESO-1 gene also encodes two overlapping, but non-cross-reactive, HLA-DRB1*0401-presented peptides that are recognized by CD4+ T cells. The NY-ESO-1 119–143 peptide was able to induce specific CD4+ T cells in vitro from both an HLA-DRB1*0401 + normal donor and an HLA-DRB1*0401 + patient with melanoma. Bulk and cloned CD4+ T cells produced IFN- specifically in response to, and also lysed, T2.DR4 cells pulsed with peptide NY-ESO-1 119–143 and the autologous tumor cell line, but not a DRB1*0401 + melanoma cell line that does not express NY-ESO-1. Interestingly, the NY-ESO 119–143 peptide contains two overlapping putative "core" epitopes recognized by non-cross-reactive anti-NY-ESO-1 119–143 CD4+ T-cell clones. Taken together, these data support the use of this novel DR4-restricted tumor peptide, NY-ESO-1 119–143 , or its two "sub-epitopes" in immunotherapeutic trials designed to generate or enhance specific CD4+ T-cell responses against tumors expressing NY-ESO-1 in vivo . http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

NY-ESO-1 Encodes DRB1*0401-restricted Epitopes Recognized by Melanoma-reactive CD4+ T Cells

NY-ESO-1 Encodes DRB1*0401-restricted Epitopes Recognized by Melanoma-reactive CD4+ T Cells

Cancer Research , Volume 60 (17): 4946 – Sep 1, 2000

Abstract

The NY-ESO-1 gene is expressed by a range of human tumors and encodes HLA-A2-restricted melanoma peptides recognized by CD8+ CTLs. Here we report that the NY-ESO-1 gene also encodes two overlapping, but non-cross-reactive, HLA-DRB1*0401-presented peptides that are recognized by CD4+ T cells. The NY-ESO-1 119–143 peptide was able to induce specific CD4+ T cells in vitro from both an HLA-DRB1*0401 + normal donor and an HLA-DRB1*0401 + patient with melanoma. Bulk and cloned CD4+ T cells produced IFN- specifically in response to, and also lysed, T2.DR4 cells pulsed with peptide NY-ESO-1 119–143 and the autologous tumor cell line, but not a DRB1*0401 + melanoma cell line that does not express NY-ESO-1. Interestingly, the NY-ESO 119–143 peptide contains two overlapping putative "core" epitopes recognized by non-cross-reactive anti-NY-ESO-1 119–143 CD4+ T-cell clones. Taken together, these data support the use of this novel DR4-restricted tumor peptide, NY-ESO-1 119–143 , or its two "sub-epitopes" in immunotherapeutic trials designed to generate or enhance specific CD4+ T-cell responses against tumors expressing NY-ESO-1 in vivo .

Loading next page...
 
/lp/american-association-of-cancer-research/ny-eso-1-encodes-drb1-0401-restricted-epitopes-recognized-by-melanoma-KKkFM4HISU

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 2000 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

The NY-ESO-1 gene is expressed by a range of human tumors and encodes HLA-A2-restricted melanoma peptides recognized by CD8+ CTLs. Here we report that the NY-ESO-1 gene also encodes two overlapping, but non-cross-reactive, HLA-DRB1*0401-presented peptides that are recognized by CD4+ T cells. The NY-ESO-1 119–143 peptide was able to induce specific CD4+ T cells in vitro from both an HLA-DRB1*0401 + normal donor and an HLA-DRB1*0401 + patient with melanoma. Bulk and cloned CD4+ T cells produced IFN- specifically in response to, and also lysed, T2.DR4 cells pulsed with peptide NY-ESO-1 119–143 and the autologous tumor cell line, but not a DRB1*0401 + melanoma cell line that does not express NY-ESO-1. Interestingly, the NY-ESO 119–143 peptide contains two overlapping putative "core" epitopes recognized by non-cross-reactive anti-NY-ESO-1 119–143 CD4+ T-cell clones. Taken together, these data support the use of this novel DR4-restricted tumor peptide, NY-ESO-1 119–143 , or its two "sub-epitopes" in immunotherapeutic trials designed to generate or enhance specific CD4+ T-cell responses against tumors expressing NY-ESO-1 in vivo .

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Sep 1, 2000

There are no references for this article.